Health Care·Biotechnology·$5.5B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.76 | N/A | -9.67% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.76 | N/A | -9.67% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management acknowledged the challenges faced in the quarter but emphasized their commitment to ongoing projects. They did not offer specific guidance for future performance.
Management did not provide specific revenue guidance for the upcoming quarters.
The company is focused on advancing its clinical programs despite the EPS miss.
The earnings report indicates that Scholar Rock is still in a development phase, with a notable EPS miss. The stock's slight decline of 0.52% reflects investor concerns about the lack of revenue updates and future guidance. Overall, the company remains focused on its clinical programs, but uncertainty may weigh on investor sentiment.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AIR PRODS & CHEMS IN
May 10, 2021